Poly (ADP-ribose) polymerase (PARP) inhibitors represent a groundbreaking class of targeted cancer therapies that have significantly advanced the treatment of various cancers, particularly those with specific genetic mutations8, 9. This evidence concerns the gene PARP1 and cancer.